Trial · NCT06045806
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Up to approximately 50 months after the first participant is randomized | PFS as assessed by Independent Review Committee (IRC) |
| Secondary | Overall Survival (OS) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Percentage of Participants with Sustained Minimal Residual Disease Negative (MRDneg) Complete Response (CR) for 12 months | From randomization up to 60 months from randomization | |
| Secondary | Percentage of Participants with Minimal Residual Disease Negative (MRDneg) Complete Response (CR) | From randomization up to 15 months from randomization | |
| Secondary | Event-Free Survival (EFS) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Duration of Response (DOR) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Percentage of Participants with Complete Response (CR) | Up to approximately 60 months after the last participant is randomized | CR as assessed by IRC |
| Secondary | Time to Progression (TTP) | Up to approximately 60 months after the last participant is randomized | Progression as assessed by IRC |
| Secondary | Progression post-next line of treatment (PFS2) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Time to Next Treatment (TTNT) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Number of Participants Experiencing Adverse Events (AEs) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Number of Participants Experiencing Adverse Events of Special Interest (AESI) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Time of Maximum Observed Plasma Concentration (Tmax) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Area Under the Curve (AUC) from time zero to 28 days post infusion (AUC [0- 28D]) | Up to 28 days post infusion | |
| Secondary | Time of Last Measurable Observed Plasma Concentration (Tlast) | Up to approximately 60 months after the last participant is randomized | |
| Secondary | Time-to-Definitive Deterioration | Up to approximately 50 months after the first participant is randomized | Time-to-definitive deterioration based on the European Organization for Research and Treatment of Cancer core quality of life questionnaire EORTC QLQ-C30 global health status/quality of life subscale |
| Secondary | Mean Change from Baseline in EORTC QLQ-C30 Selected Subscales | Up to approximately 50 months after the first participant is randomized | The following subscales on the European Organization for Research and Treatment of Cancer core quality of life questionnaire EORTC QLQ-C30 will be assessed: * Global health status/quality of life * Physical Functioning * Fatigue * Pain |
| Secondary | Mean Change from Baseline in EORTC QLQ-MY20 Selected Subscales | Up to approximately 50 months after the first participant is randomized | The following subscales on the European Organization for Research and Treatment of Cancer core quality of life questionnaire EORTC QLQ-MY20 will be assessed: * Disease symptoms * Side-effects of treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06045806/registered